PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7716065-6 1995 When slices were exposed to alpha-MSH and haloperidol, the latter blocked the alpha-MSH effect of inducing an increase in the content of cAMP. Haloperidol 42-53 proopiomelanocortin Rattus norvegicus 78-87 9147288-4 1997 Despite the obvious difference in D2-R gene expression, NIL POMC mRNA in both rat strains was regulated in an identical manner following 4 d in vivo bromocriptine or haloperidol treatment. Haloperidol 166-177 proopiomelanocortin Rattus norvegicus 60-64 7518029-2 1994 In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%). Haloperidol 18-29 proopiomelanocortin Rattus norvegicus 82-102 7518029-2 1994 In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%). Haloperidol 18-29 proopiomelanocortin Rattus norvegicus 104-108 8132649-3 1994 In cDNA libraries prepared from the neurointermediate pituitaries of these rats, pro-opiomelanocortin (POMC) expression exhibited the expected decrease in response to bromocriptine, and increase in response to haloperidol. Haloperidol 210-221 proopiomelanocortin Rattus norvegicus 81-101 8132649-3 1994 In cDNA libraries prepared from the neurointermediate pituitaries of these rats, pro-opiomelanocortin (POMC) expression exhibited the expected decrease in response to bromocriptine, and increase in response to haloperidol. Haloperidol 210-221 proopiomelanocortin Rattus norvegicus 103-107 2168526-5 1990 In nonstressed animals the administration of the beta 2-adrenergic agonist metaproterenol increased the plasma levels of alpha-MSH, and the effect of this drug was augmented if the inhibitory dopaminergic tone on alpha-MSH secretion was blocked by the administration of the DA antagonist haloperidol. Haloperidol 288-299 proopiomelanocortin Rattus norvegicus 121-130 8115018-4 1993 We have therefore measured POMC gene expression and peptide content in the MBH of chronically castrated male and female rats in response to the dopamine antagonist haloperidol, and in intact or sex steroid replaced animals in response to the dopamine agonist pergolide. Haloperidol 164-175 proopiomelanocortin Rattus norvegicus 27-31 1331668-8 1992 In the intermediate lobe of the pituitary, BRO markedly depressed (30% of control values) and HAL increased by 50% the levels of POMC mRNA. Haloperidol 94-97 proopiomelanocortin Rattus norvegicus 129-133 1331668-9 1992 The present data clearly demonstrate that POMC mRNA levels are differently regulated by dopamine in the intermediate lobe of the pituitary and the arcuate nucleus and that the effects of BRO and HAL on arcuate POMC mRNA are not mediated by the pituitary gland. Haloperidol 195-198 proopiomelanocortin Rattus norvegicus 210-214 1316544-6 1992 Neurointermediate lobe levels of PC1, PC2, and POMC mRNA increased 2- to 6-fold in rats treated with haloperidol, while they decreased to 10-25% of their control values after bromocriptine treatment. Haloperidol 101-112 proopiomelanocortin Rattus norvegicus 47-51 1656298-4 1991 Addition of alpha-MSH significantly increased the DA activity in ventromedial nucleus (VMN) and zona incerta, but this action is unlikely to account for its stimulation of sexual receptivity, since this effect was not blocked by 0.1 mg/kg haloperidol. Haloperidol 239-250 proopiomelanocortin Rattus norvegicus 12-21 8243288-5 1993 Intermediate lobe proDyn gene expression was not regulated by dopamine, in contrast to intermediate lobe POMC mRNA levels, which were increased with haloperidol and decreased with bromocriptine treatment, as expected. Haloperidol 149-160 proopiomelanocortin Rattus norvegicus 105-109 2168526-5 1990 In nonstressed animals the administration of the beta 2-adrenergic agonist metaproterenol increased the plasma levels of alpha-MSH, and the effect of this drug was augmented if the inhibitory dopaminergic tone on alpha-MSH secretion was blocked by the administration of the DA antagonist haloperidol. Haloperidol 288-299 proopiomelanocortin Rattus norvegicus 213-222 2109273-0 1990 Differential effects of haloperidol on the rat pituitary: decreased biosynthesis, processing and release of anterior lobe pro-opiomelanocortin. Haloperidol 24-35 proopiomelanocortin Rattus norvegicus 122-142 2361568-5 1990 The effects of acute or chronic postnatal treatment with a dopamine antagonist (haloperidol) or a dopamine agonist (bromocriptine) show that the physiological dopaminergic inhibitory control of POMC gene expression operates as early as postnatal day 5. Haloperidol 80-91 proopiomelanocortin Rattus norvegicus 194-198 2109273-1 1990 The effects of chronic haloperidol treatment on pro-opiomelanocortin (POMC) synthesis, processing, and release in the anterior (AL) and intermediate (IL) lobes of the rat pituitary were studied. Haloperidol 23-34 proopiomelanocortin Rattus norvegicus 48-68 2109273-2 1990 In the IL, 14 days of haloperidol administration promoted an increase in the level of POMC mRNA, and a corresponding elevation of levels of beta-endorphin (beta E), alpha-melanocyte-stimulating hormone (MSH), and gamma 3 MSH. Haloperidol 22-33 proopiomelanocortin Rattus norvegicus 86-90 2109273-2 1990 In the IL, 14 days of haloperidol administration promoted an increase in the level of POMC mRNA, and a corresponding elevation of levels of beta-endorphin (beta E), alpha-melanocyte-stimulating hormone (MSH), and gamma 3 MSH. Haloperidol 22-33 proopiomelanocortin Rattus norvegicus 165-201 2109273-2 1990 In the IL, 14 days of haloperidol administration promoted an increase in the level of POMC mRNA, and a corresponding elevation of levels of beta-endorphin (beta E), alpha-melanocyte-stimulating hormone (MSH), and gamma 3 MSH. Haloperidol 22-33 proopiomelanocortin Rattus norvegicus 203-206 2109273-2 1990 In the IL, 14 days of haloperidol administration promoted an increase in the level of POMC mRNA, and a corresponding elevation of levels of beta-endorphin (beta E), alpha-melanocyte-stimulating hormone (MSH), and gamma 3 MSH. Haloperidol 22-33 proopiomelanocortin Rattus norvegicus 221-224 2109273-8 1990 These results suggest that pituitary POMC biosynthesis, processing and release are under at least partial dopaminergic control in both the IL and the AL of the pituitary, but by different mechanisms; chronic haloperidol treatment upregulates the POMC system in IL, but downregulates it in AL, despite similarities of the responses of both lobes to acute haloperidol challenge. Haloperidol 208-219 proopiomelanocortin Rattus norvegicus 37-41 2109273-8 1990 These results suggest that pituitary POMC biosynthesis, processing and release are under at least partial dopaminergic control in both the IL and the AL of the pituitary, but by different mechanisms; chronic haloperidol treatment upregulates the POMC system in IL, but downregulates it in AL, despite similarities of the responses of both lobes to acute haloperidol challenge. Haloperidol 208-219 proopiomelanocortin Rattus norvegicus 246-250 2109273-8 1990 These results suggest that pituitary POMC biosynthesis, processing and release are under at least partial dopaminergic control in both the IL and the AL of the pituitary, but by different mechanisms; chronic haloperidol treatment upregulates the POMC system in IL, but downregulates it in AL, despite similarities of the responses of both lobes to acute haloperidol challenge. Haloperidol 354-365 proopiomelanocortin Rattus norvegicus 37-41 1967627-4 1990 The intraperitoneal injection of the dopamine receptor blocker, haloperidol (2 mg/kg), 30 min before the injection of alpha-MSH into the ME prevented the inhibitory effect of alpha-MSH on the release of LH and prolactin. Haloperidol 64-75 proopiomelanocortin Rattus norvegicus 118-127 1967627-4 1990 The intraperitoneal injection of the dopamine receptor blocker, haloperidol (2 mg/kg), 30 min before the injection of alpha-MSH into the ME prevented the inhibitory effect of alpha-MSH on the release of LH and prolactin. Haloperidol 64-75 proopiomelanocortin Rattus norvegicus 175-184 206851-3 1978 Haloperidol caused a rapid increase, alpha-MPT a slow increase, and CB 154 a rapid decrease in serum alpha-MSH. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 101-110 3416822-7 1988 Haloperidol treatment dramatically increased the number of dark melanotropes and the amount of POMC mRNA in each cell and eliminated the cellular heterogeneity in both staining properties and the distribution of POMC mRNA. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 95-99 3416822-7 1988 Haloperidol treatment dramatically increased the number of dark melanotropes and the amount of POMC mRNA in each cell and eliminated the cellular heterogeneity in both staining properties and the distribution of POMC mRNA. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 212-216 2839845-3 1988 Administration of the DA antagonist haloperidol prevented the decline in serum alpha MSH levels following arcuate nucleus stimulation, but had no effect on serum alpha MSH concentrations in sham-stimulated GBL-treated rats. Haloperidol 36-47 proopiomelanocortin Rattus norvegicus 79-88 2959468-5 1987 In the NIL, the dopamine agonist bromocriptine reduced and the antagonist haloperidol raised both POMC mRNA and ir-beta EP content. Haloperidol 74-85 proopiomelanocortin Rattus norvegicus 98-102 2959468-7 1987 DM abolished the haloperidol-induced increase in NIL ir-beta EP content but further increased the haloperidol-induced rise in POMC mRNA. Haloperidol 98-109 proopiomelanocortin Rattus norvegicus 126-130 2959468-9 1987 In DM-treated rats, haloperidol partially restored AP ir-beta EP and POMC mRNA to control untreated levels. Haloperidol 20-31 proopiomelanocortin Rattus norvegicus 69-73 2959468-11 1987 The effects of DM on the NIL, both alone or with haloperidol, suggest that glucocorticoids may have both direct and indirect effects on POMC gene expression in this tissue. Haloperidol 49-60 proopiomelanocortin Rattus norvegicus 136-140 3475692-7 1987 In vivo administration of a dopamine agonist (bromocryptine) or antagonist (haloperidol) caused a decrease or increase, respectively, in the amount of true glandular kallikrein mRNA in the neurointermediate lobe of both sexes that closely paralleled changes in proopiomelanocortin mRNA levels. Haloperidol 76-87 proopiomelanocortin Rattus norvegicus 261-280 2409428-7 1985 On the other hand, a time-course of plasma alpha-MSH levels after DE gamma E administration resembled the one which has been seen after haloperidol injection. Haloperidol 136-147 proopiomelanocortin Rattus norvegicus 43-52 466509-2 1979 While treatment with haloperidol increased alpha-MSH levels in the plasma concentration of alpha-MSH in the CSF showed little change. Haloperidol 21-32 proopiomelanocortin Rattus norvegicus 43-52 466509-2 1979 While treatment with haloperidol increased alpha-MSH levels in the plasma concentration of alpha-MSH in the CSF showed little change. Haloperidol 21-32 proopiomelanocortin Rattus norvegicus 91-100 2575547-4 1989 We report here that 5-day administration of the DA antagonist haloperidol led to significant increases in both D2-R mRNA and POMC mRNA in the NIL; the DA agonist bromocriptine caused a significant decrease in NIL POMC mRNA with no parallel change in D2-R mRNA. Haloperidol 62-73 proopiomelanocortin Rattus norvegicus 125-129 2575547-4 1989 We report here that 5-day administration of the DA antagonist haloperidol led to significant increases in both D2-R mRNA and POMC mRNA in the NIL; the DA agonist bromocriptine caused a significant decrease in NIL POMC mRNA with no parallel change in D2-R mRNA. Haloperidol 62-73 proopiomelanocortin Rattus norvegicus 213-217 2938933-4 1986 Haloperidol administration produced parallel and essentially equivalent increases in acetyltransferase activity, POMC mRNA levels, and the content and secretion of POMC-derived peptides in the neurointermediate pituitary. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 113-117 2938933-4 1986 Haloperidol administration produced parallel and essentially equivalent increases in acetyltransferase activity, POMC mRNA levels, and the content and secretion of POMC-derived peptides in the neurointermediate pituitary. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 164-168 6572972-4 1983 Administration of a dopamine receptor antagonist, haloperidol (2 mg/kg per day), to adult female rats resulted in a 3- to 5-fold increase in POMC mRNA level in the NIP. Haloperidol 50-61 proopiomelanocortin Rattus norvegicus 141-145 6572972-7 1983 The effect of haloperidol and ergocryptine on POMC mRNA in the NIP is time- and dose-dependent. Haloperidol 14-25 proopiomelanocortin Rattus norvegicus 46-50 6572972-8 1983 The elevation of POMC mRNA content in the NIP by haloperidol can be observed as early as 6 hr after treatment. Haloperidol 49-60 proopiomelanocortin Rattus norvegicus 17-21 6280978-0 1982 Chronic haloperidol treatment increases the level of in vitro translatable messenger ribonucleic acid coding for the beta-endorphin/adrenocorticotropin precursor proopiomelanocortin in the pars intermedia of the rat pituitary. Haloperidol 8-19 proopiomelanocortin Rattus norvegicus 162-181 6280978-2 1982 Incorporation of [3H]phenylalanine into isolated neurointermediate pituitaries of haloperidol-treated rats revealed an increase in the amount of label incorporated into the beta-endorphin/ACTH precursor proopiomelanocortin (POMC) to a similar extent (about 80%) but had essentially no effect on the conversion of the precursor into beta-lipotropin and beta-endorphin. Haloperidol 82-93 proopiomelanocortin Rattus norvegicus 203-222 6280978-2 1982 Incorporation of [3H]phenylalanine into isolated neurointermediate pituitaries of haloperidol-treated rats revealed an increase in the amount of label incorporated into the beta-endorphin/ACTH precursor proopiomelanocortin (POMC) to a similar extent (about 80%) but had essentially no effect on the conversion of the precursor into beta-lipotropin and beta-endorphin. Haloperidol 82-93 proopiomelanocortin Rattus norvegicus 224-228 6280978-5 1982 Time-course studies revealed a parallelism between the effect of haloperidol on the level of in vitro translatable mRNA coding for POMC and the ability of the drug to increase the concentrations of beta-endorphin in the neurointermediate pituitary. Haloperidol 65-76 proopiomelanocortin Rattus norvegicus 131-135 6280978-7 1982 These findings suggest that the chronic blockade of dopaminergic receptors by haloperidol causes a reversible increase in the beta-endorphin biosynthesis in the rat intermediate pituitary at the pretranslational level by markedly increasing the level of translatable mRNA coding for POMC. Haloperidol 78-89 proopiomelanocortin Rattus norvegicus 283-287 174889-17 1976 Haloperidol injection was followed by a large increase in plasma alpha-MSH, whereas ACTH levels increased similarly after saline and Haloperidol injection. Haloperidol 0-11 proopiomelanocortin Rattus norvegicus 65-74